OrbiMed Raises Two New Life Sciences Funds Totaling $3B

By Grace Kim

OrbiMed has closed two new life sciences funds worth a combined $3 billion, according to BioSpace, with one of the vehicles aimed squarely at Asia.

The haul marks one of the larger private capital commitments to drug development and medical investment this cycle. The New York-based firm, one of the oldest healthcare-dedicated investment houses in the industry, did not break out the split between the two funds in the report.

What does the $3B buy?

The twin funds give OrbiMed fresh dry powder across life sciences — from biotech startups to later-stage healthcare companies. The Asia-directed vehicle signals where the firm sees the next leg of growth: the report notes the fund will aim for opportunities across the region's healthcare and pharmaceutical sector.

That geographic split matters. Asia's biotech pipeline has drawn escalating Western capital in recent years, and a dedicated fund lets OrbiMed underwrite deals without competing against its own global book.

Why two funds instead of one?

Running separate vehicles lets OrbiMed ring-fence regional strategy. The global fund can chase deals in the U.S. and Europe, while the Asia fund builds a bench of regional expertise — a structure several multi-region healthcare investors have adopted as cross-border biotech deals grow more complex.

The $3 billion total also lands at a moment when biotech funding has been selective. Firms with capital ready to deploy tend to see stronger deal terms when the broader market tightens.

What comes next?

Expect deployment announcements from both vehicles in the coming quarters, with the Asia fund's first deals likely to serve as the clearest signal of OrbiMed's regional priorities.